Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer

Published:2023 Issue:3 Volume:124 Page:199-215
ISSN:1214-6994
Container-title:Prague Medical Report
language:en
Short-container-title:Prague Med. Rep.

Author:

Staša Judita,Gregorová Jana,Slanař Ondřej,Šíma Martin

Abstract

Targeted therapy with protein kinase inhibitors (PKIs) represents one of the important treatment options for non-small cell lung cancer (NSCLC). It has contributed to improve patients’ survival and quality of life significantly. These anticancer drugs are administrated orally in flat-fixed doses despite the well-known large interpatient pharmacokinetic variability and the possible need for dose individualization. To optimize and individualize dosing of PKIs, and thereby increasing the effectiveness and safety of the treatment, therapeutic drug monitoring (TDM) is the most frequently mentioned method. Unlike other areas of medicine, TDM has been rather exceptional in oncological practise since there is a little evidence or no data for concentration-effect relationships of PKIs. Therefore, the aim of this review is to summarize the pharmacokinetic characteristics of PKIs and provide the evidence supporting the use of TDM for personalised treatment of patients with NSCLC.

Publisher

Charles University in Prague, Karolinum Press

Subject

General Medicine

Reference61 articles.

1. Afatinib (2012) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013 /201292Orig1s000ClinPharmR.pdf (Accessed 10 March 2023)

2. Alectinib (2016) Committee for Medicinal Products for Human Use. European Medicines Agency. Alecensa. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report /alecensa-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)

3. Role of Tyrosine Kinase Inhibitors in Cancer Therapy

4. Brigatinib (2017) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation NDA 208772 ALUNBRIG (brigatinib). Available at: www.accessdata.fda.gov /drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf (Accessed 10 March 2023)

5. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer